CG
DNLI icon

Cutler Group’s Denali Therapeutics DNLI Stock Holding History

Cutler Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,100
Closed -$2K – 3696
2023
Q1 		$2K Sell
1,100
-2,900
-73% -$79.8K ﹤0.01% 3118
2022
Q4 		$18K Hold
4,000
– – ﹤0.01% 2278
2022
Q3 		$21K Buy
+4,000
New +$130K ﹤0.01% 2572
2021
Q2 		– Sell
-600
Closed -$2K – 5802
2021
Q1 		$2K Buy
+600
New +$40.2K ﹤0.01% 4892
2020
Q2 		– Sell
-1,000
Closed -$6K – 4465
2020
Q1 		$6K Buy
+1,000
New +$20.9K ﹤0.01% 2977

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cutler Group's DNLI Position: Q1 2024 in Review

Cutler Group held its Denali Therapeutics (DNLI) position steady in Q1 2024 at 400 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

Cutler Group first reported a position in DNLI in Q4 2018 and has held it in 16 quarters since. The position peaked at $75K in Q4 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Cutler Group held 400 shares of Denali Therapeutics worth $8K as of Q1 2024.
  • Cutler Group left its Denali Therapeutics share count unchanged in Q1 2024.
  • Denali Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1367 holding.
  • Cutler Group first reported a position in Denali Therapeutics in Q4 2018 and has held it in 16 quarters since.
  • Cutler Group's Denali Therapeutics position peaked at $75K in Q4 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.